Australian Advocates Call for Subsidised Weight-Loss Drugs for Women with PMOS

Australian health advocates are urging for subsidised access to weight-loss drugs for women with Polycystic Ovary Syndrome (PMOS). Currently, GLP-1 drugs used to treat the condition are prescribed off-label as they lack specific approval from the Therapeutic Goods Administration (TGA). This call highlights the need for formal recognition and support for effective treatments.

Originally published by gnews